Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial

Journal:
Nature Medicine
Published:
Affiliations:
20
Authors:
24
Institutions Authors Share
Merck & Co, United States of America (USA)
7.000000
0.29
Vanderbilt University Medical Center (VUMC), United States of America (USA)
1.000000
0.04
Fox Chase Cancer Center (FCCC), United States of America (USA)
1.000000
0.04
Dnipro State Medical University (DSMU), Ukraine
1.000000
0.04
Russian Scientific Center of Roentgen Radiology (RSCRR), Russia
1.000000
0.04
The Christie NHS Foundation Trust, United Kingdom (UK)
1.000000
0.04
Moscow Central Clinical Hospital, Russia
1.000000
0.04
CHU de Québec, UL, Canada
1.000000
0.04
P.A. Hertzen Moscow Cancer Research Institute, Russia
1.000000
0.04
Hospital of the University of Montreal (CHUM), Canada
1.000000
0.04
University Hospital Olomouc, PU, Czech Republic
1.000000
0.04
Hospital de Clínicas de Porto Alegre (HCPA), UFRGS, Brazil
1.000000
0.04
St. Vincent's University Hospital, Ireland
1.000000
0.04
Klinikum Stuttgart, Germany
1.000000
0.04
Bell Land General Hospital, Japan
1.000000
0.04
Queen Mary University of London (QMUL), United Kingdom (UK)
1.000000
0.04
Sumy State University (SSU), Ukraine
0.500000
0.02
Sumy Regional Oncology Center, Ukraine
0.500000
0.02
Centre Antoine-Lacassagne (CAL), France
0.500000
0.02
Université Côte d'Azur (UniCA), France
0.500000
0.02